Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Freudenstadt – page 49

721 clinical trials in Freudenstadt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Freudenstadt at a glance
721
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

721 trials in Freudenstadt

Open in trial search

Study on Radiotherapy and Durvalumab for Patients with Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Swiss Group for Clinical Cancer Research

Study on Gene Therapy with VTX-801 and Copper (64Cu) Chloride for Adults with Wilson's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Copper (64CU) chloride
  • Sponsor:Vivet Therapeutics

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study Comparing Sacituzumab Govitecan with Standard Treatment for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study of [177Lu]Lu-NeoB and Capecitabine for Patients with Advanced Breast Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Novartis Pharma AG

Ataxia telangiectasia

Not recruiting

Study on the Effects of EryDex (Dexamethasone Sodium Phosphate) for Children Aged 6-9 with Ataxia Telangiectasia

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Quince Therapeutics S.p.A.

Long-Term Safety Study of GT005 for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration Previously Treated in a Gyroscope Study

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GT005
  • Sponsor:Novartis Pharma AG

Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IO102 hydrochloride
  • Sponsor:Io Biotech ApS

Neurofibromatosis

Not recruiting

Study on Selumetinib for Children Aged 1 to 6 with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Selumetinib
  • Sponsor:AstraZeneca AB

Study on the Safety and Effectiveness of Padeliporfin Therapy for Patients with Low-Grade Upper Tract Urothelial Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Padeliporfin
  • Sponsor:Steba Biotech S.A.

Uveal melanoma+2

Not recruiting

Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Freudenstadt

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical studies focusing on hormone receptor-positive HER2-negative breast cancer, exploring combination therapies with endocrine treatment approaches.

  • Advanced/Metastatic Breast Cancer
  • Hormone Receptor Studies
  • Digital Side Effect Management

Research aims to evaluate treatment effectiveness and patient outcomes through systematic monitoring and assessment.

02 Biliary Tract Cancer Studies

Groundbreaking research investigating advanced biliary tract cancers through combination therapy approaches using immunotherapy and chemotherapy.

  • First-line Treatment Assessment
  • Combination Therapy Safety
  • Multicentre Clinical Evaluation

The research focuses on evaluating novel treatment combinations to improve patient outcomes in advanced disease stages.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.